Increased levels of a minor glycoform of acetylcholinesterase in Alzheimer's disease brain and cerebrospinal fluid

Abstract

With the advent of effective therapeutic agents for the treatment of Alzheimer's disease, accurate diagnosis will become increasingly important. To date, clinical diagnosis based on neuropsychological assessment is time consuming and often inaccurate. A number of studies have shown that certain cerebrospinal fluid proteins are altered in Alzheimer's disease. There is a need to identify new biomarkers which can be used alone or in combination with other biomarkers such as β‐Amyloid42 and tau to increase confidence in clinical diagnosis.